FDA WARNING_LETTER - SilveryGuy - August 12, 2020
On August 14, 2020, the FDA and FTC issued a Warning Letter to Silveryguy.com, an Amazon Associate, for promoting and participating in the sale of "Colloidal Silver" with unproven COVID-19 claims. The FDA reviewed the company's website (www.silveryguy.com) and Facebook page (www.facebook.com/silveryguy/) on August 5 and 12, 2020.
The violations include marketing Colloidal Silver with claims implying it can mitigate, prevent, treat, diagnose, or cure COVID-19. This causes the product to be an unapproved new drug under Section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and a misbranded drug under Section 502 (21 U.S.C. § 352). Introducing or delivering these products into interstate commerce is prohibited under Sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)), and misbranding a drug held for sale after interstate shipment is prohibited under Section 301(k) (21 U.S.C. § 331(k)).
The letter cites the public health emergency and national emergency declarations related to COVID-19. Sil
ID · b6a70a82-d025-484b-9f8c-4dd2bf619e4d
Full citation text and observation details available on the Dashboard.